4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

(19)

(11)

EP 3 774 775 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	15.11.2023 Bulletin 2023/46

(45)	Mention of the grant of the patent:
	11.10.2023 Bulletin 2023/41

(21)	Application number: 19725404.8

(22)	Date of filing: 11.04.2019

(51)

International Patent Classification (IPC):

C07D 401/14^(2006.01)
C07D 403/14^(2006.01)
A61K 31/517^(2006.01)

C07D 405/14^(2006.01)
A61P 31/18^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07D 401/14; C07D 403/14; C07D 405/14; A61P 31/18

(86)	International application number:
	PCT/IB2019/052990

(87)	International publication number:
	WO 2019/198024 (17.10.2019 Gazette 2019/42)

(54)

4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

4-OXO-3,4-DIHYDROCHINAZOLIN-VERBINDUNGEN ALS INHIBITOREN DER REPLIKATION DES MENSCHLICHEN IMMUNDEFIZIENZVIRUS

COMPOSÉS DE 4-OXO-3,4-DIHYDROQUINAZOLINE UTILISÉS EN TANT QU'INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

11.04.2018 US 201862655881 P
26.06.2018 US 201862689995 P
18.09.2018 US 201862732741 P
25.10.2018 US 201862750336 P

(43)	Date of publication of application:
	17.02.2021 Bulletin 2021/07

(73)	Proprietor: VIIV Healthcare UK (No.5) Limited
	Stevenage SG1 2NY (GB)

(72)

Inventors:

BELEMA, Makonen
Wallingford, Connecticut 06492 (US)
BENDER, John A.
Wallingford, Connecticut 06492 (US)
FRENNESSON, David B.
Wallingford, Connecticut 06492 (US)
GILLIS, Eric P
Branford, Connecticut 06405 (US)
IWUAGWU, Christiana
Branford, Connecticut 06405 (US)
KADOW, John F
Branford, Connecticut 06405 (US)
NAIDU, B. Narasimhulu
Branford, Connecticut 06405 (US)
PARCELLA, Kyle E.
Branford, Connecticut 06405 (US)
PEESE, Kevin M.
Branford, Connecticut 06405 (US)
RAJAMANI, Ramkumar
Wallingford, Connecticut 06492 (US)
SAULNIER, Mark G.
Wallingford, Connecticut 06492 (US)
WANG, Alan Xiangdong
Wallingford, Connecticut 06492 (US)
BOWSHER, Michael S
Branford, CT 06405 (US)
PATEL, Manoj
Branford, CT 06405 (US)

(74)	Representative: Billson, Siân Catherine et al
	GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)

(56)

References cited: :

WO-A1-2013/006738
WO-A1-2014/110298
WO-A1-2018/203235
WO-A1-2020/084492

WO-A1-2014/110297
WO-A1-2016/033243
WO-A1-2020/084480
WO-A2-2014/134566

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).